Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India
Authors:
- Krishna PandeyKPKrishna Pandey
- Biplab PalBPBiplab Pal
- Niyamat Ali SiddiquiNSNiyamat Ali Siddiqui
- Vidya Nand Rabi DasVDVidya Nand Rabi Das
- Krishna MurtiKMKrishna Murti
- Chandra Shekhar LalCLChandra Shekhar Lal
- Neena VermaNVNeena Verma
- Rajendra BabuRBRajendra Babu
- Vahab AliVAVahab Ali
- Rakesh KumarRKRakesh Kumar
- Pradeep DasPDPradeep Das
- 8 November 2017
- journal article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 97 (5) , 1498-1502
Abstract
Liposomal amphotericin B is being used increasingly to reduce the burden of kala-azar from the Indian subcontinent. There are studies which have evaluated efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in all age groups. However, the only study that specifically addressed treatment of childhood visceral leishmaniasis did not include all ages or document renal and liver function. We, therefore, felt it was important to reassess the efficacy and safety of single dose liposomal amphotericin B in children and adolescents. A total of 100 parasitologically confirmed visceral leishmaniasis patients aged < 15 years were included in this study. Participants consisted of 65 males and 35 females. All of them had come from the endemic region of Bihar. They were administered one dose intravenous infusion of liposomal amphptericin B at 10 mg/kg body weight. Efficacy was assessed as initial and final cure at 1 and 6 months, respectively, and safety of all participants who were recruited in the study. The initial and final cure rate by per protocol analysis was 100% and 97.9%, respectively. Chills and rigors were the most commonly occurring adverse events (AEs). All the AEs were mild in intensity, and none of the patients experienced any serious AEs. No patients developed nephrotoxicity. Our finding indicates that liposomal amphotericin B at 10 mg/kg body weight is safe and effective in children. Results of our study support the use of single dose liposomal amphotericin B in all age group populations for elimination of kala-azar from the Indian subcontinent.Keywords
This publication has 20 references indexed in Scilit:
- Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in BangladeshPLOS Neglected Tropical Diseases, 2015
- Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility studyThe Lancet Global Health, 2014
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of UseClinical Infectious Diseases, 2012
- Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, IndiaThe American Journal of Tropical Medicine and Hygiene, 2010
- Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid FormulationsClinical Infectious Diseases, 2004
- Single‐Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter StudyClinical Infectious Diseases, 2003
- Two Doses of a Lipid Formulation of Amphotericin B for the Treatment of Mediterranean Visceral LeishmaniasisClinical Infectious Diseases, 2003
- Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.The American Journal of Tropical Medicine and Hygiene, 2002
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trialCommentary: cost and resistance remain issuesBMJ, 2001